Introduction {#sec1-1}
============

Radioresistance and chemoresistance are important contributing factors towards the failure of tumour cell kill and subsequent eradication of tumours. Strategies to overcome radioresistance or enhance radiation sensitivity include classically altering the radiation fractionation wherein a higher radiation dose is given to the tumour to overcome intrinsic radioresistance (hyperfractionation) or compensate for the tumour repopulation by reducing the overall treatment time (accelerated fractionation)[@ref1][@ref2][@ref3][@ref4][@ref5]. A second approach is to use a combination of chemotherapy with radiotherapy, in particular concurrent chemoradiotherapy[@ref6][@ref7]. This approach has shown benefit in numerous solid cancers especially in head and neck and cervical carcinoma[@ref7][@ref8]. A third approach to overcome radioresistance is to modulate hypoxia in the tumour cells. This approach has been particularly useful in head and neck cancers where intrinsic hypoxia is a major factor contributing to tumour cell radioresistance. Trials using hypoxic sensitizers such as nitroimidazoles and hypoxic cytotoxins have been published[@ref9][@ref10][@ref11][@ref12]. Another promising approach is the use of targeted therapy concurrently with radiation, to enhance the efficacy of radiation, *e.g.*, epidermal growth factor receptor (EGFR) inhibitors like cetuximab in head and neck cancer[@ref13][@ref14], gefitinib, erlotinib and afatinib in lung cancer[@ref15][@ref16][@ref17][@ref18], and vascular endothelial growth factor (VEGF) inhibitor, bevacizumab in colon cancer[@ref19][@ref20]. The advantage of targeted therapy is that these have a reasonably high therapeutic ratio although drug specific toxicity may occur. In this respect targeting the phosphatidyl inositol 3-kinase/protein kinase B (PI3-K/AKT) signal transduction pathway considered to be a major pathway in radiation resistance may enhance the radiosensitivity of tumours[@ref21][@ref22]. The PI3-K/AKT pathway is overexpressed in a variety of tumours ([Table I](#T1){ref-type="table"}). Since this pathway is constitutively overexpressed in tumour cells, sparing the normal cells makes it an excellent target for enhancing the radiosensitivity.

###### 

Expression of AKT in various cancers
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Though the development in the field of targeted pharmacotherapy is ongoing, the process of developing novel agents that would block the PI3-K/AKT pathway and bringing these into the clinic as interventional agents is a relatively tardy process especially when starting from novel compounds not previously tested in humans. In contrast, drugs or agents which are already in clinical practice for other diseases could be used as molecular targeting agents for anti-cancer therapy and adopted in clinics after testing them in thoroughly designed clinical trials thereby avoiding any delay in the process of drug development. Currently, such off-label use of drugs is being followed with anti-retroviral \[human immunodeficiency virus (HIV) protease inhibitors, HPI\'s\] drugs that inhibit AKT phosphorylation as candidates for not only anti-cancer therapy, but also for developing these agents as radiosensitizers. These compounds have been used as anti-HIV drugs in the clinics for the past decade and their safety profile is well documented in the literature. However, their use in combination with other cytotoxic therapies like radiation therapy (RT) and chemotherapy (CT) is under intense investigation.

The aim of the review was to collect available *in vitro*/*in vivo* data and data from clinical trials related to HIV protease inhibitors as radiosensitizers, and evaluate the role of HPI\'s, particularly nelfinavir, as a potential candidate drug as a radio sensitizer.

PI3-K/AKT signaling pathway and radiation resistance {#sec1-2}
====================================================

Cancer cells have a tendency to acquire resistance to radio/chemotherapy[@ref52][@ref53][@ref54]. The relevance of the PI3-K/AKT signal-transduction pathway has been shown in radioresistance[@ref52]. One of the factors responsible for resistance to therapy is overexpression/activation of oncogenes (*e.g.* EGFR, RAS) and loss of tumour suppressor gene (*e.g.* PTEN)[@ref55][@ref56][@ref57][@ref58][@ref59][@ref60][@ref61]. These molecular alterations ultimately lead to activation of PI3-K/AKT pathway which regulates important mechanisms of cellular radioresistance.

***Akt activation and events leading to DNA damage repair***: Studies have shown EGFR and RAS activation to be a major contributor to tumour radioresistance which in turn activates the PI3-K/AKT pathway thereby increasing the survival of tumour cells that have been exposed to DNA damaging agents[@ref62][@ref63]. Moreover, selectively blocking this pathway reduces the tumour cell survival after irradiation[@ref62][@ref63]. Cellular radioresistance is linked to the ability of the tumour cells to repair the DNA damage it incurs following exposure to DNA damaging agents. Repair can occur either by homologous recombination (HR) or non-homologous end joining (NHEJ) which is responsible for majority of the double strand DNA break repair. A major protein involved in the NHEJ repair machinery and radiotherapy response is the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)[@ref64]. The Akt has been shown to directly interact with DNA-PKcs through its C-terminal domain[@ref65]. Akt1 and DNA-PKcs form a functional complex after radiation exposure and promotes accumulation of DNA-PKcs and stimulates DNA-PKcs kinase activity at DNA-DSB (double strand break) site for initiating DNA-DSB repair[@ref65][@ref66][@ref67]. An alternative pathway regulating DNA-DSB repair by Akt is the upregulation of MRE11 expression after Akt activation through Akt/GSK3ß (glycogen synthase kinase-3 beta) ß-catenin/LEF-1 (lymphoid enhancer binding factor 1) pathway[@ref68]. Another protein complex-MRE11, RAD50 and NBS1 (MRN) complex accumulates at DNA-DSB sites post radiation and acts as a sensor to recruit ATM (ataxia telangectasia mutated) which in turn is activated to phosphorylate MRN complex and a variety of other proteins involved in cell-cycle control and DNA repair[@ref69]. Since targeting Akt leads to downregulation of MRE11 at the transcriptional level, role of Akt1 on DNA repair is ATM dependent. Fraser *et al*[@ref70] have shown that the activation of MRE11-ATM-RNF168 pathway induces Akt phosphorylation thus leading to an Akt-dependent enhanced repair of DNA-DSB. AKT signalling also plays an important role in DNA repair via homologous recombination (HR) pathway. It has been shown that breast cancer patients with HR deficiency have increased phospho AKT levels and similarly tumour formation due to BRCA1 deficiency is reduced by Akt1 depletion[@ref71], while in BRCA1 proficient breast cancer cells HR inhibition due to AKT1 activation is a result of cytoplasmic retention of BRCA1 and RAD51[@ref72]. In HR-deficient cells, Akt1 signalling inhibition of HR is due to impaired Chk1 nuclear localization and subsequent disruption of Chk1-Rad51 interaction[@ref73]. Thus, it is now clear that AKT signalling has contrasting effects on NHEJ and HR pathways. Since DNA-DSB repair is a combination of both NHEJ and HR repair pathways, AKT stimulates repair of DNA-DSB by the NHEJ through activation of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) which is dominant over AKT mediated impairment of DNA-DSB repair in HR-deficient cells.

EGFR signaling by the PI3-K-AKT pathway has been shown to be involved in the regulation of DNA-PKcs and, therefore, DNA repair[@ref64]. Likewise, evidence from *in vitro* studies have shown that targeting of AKT activity by small interfering RNA (siRNA) sensitizes human tumour cells to ionizing radiation[@ref62]. Therefore, EGFR/RAS-activation either by mutation or by receptor tyrosine-kinase activity is a frequent event in human malignancy, suggesting that the PI3-K/AKT-mediated repair of DNA damage might be an important mechanism of intrinsic radioresistance[@ref74].

***Autophagy and AKT signalling***: Autophagy (or programmed cell death type II) is now considered as an important process in carcinogenesis as well as tumour cell response to radiation therapy[@ref75][@ref76]. Autophagy is mainly regulated by the mammalian target of rapamycin (mTOR) pathway. Evidence suggests that PI3-K/AKT signaling plays an important role in the regulation of autophagy. Exposure of tumour cells to ionizing radiation induces autophagy. Further, inhibition of autophagy either by autophagy inhibitors[@ref77] or genetic approaches[@ref76] induces radiosensitization. Induction of autophagy through this pathway produces cytotoxic effect on the tumour cell. This is supported by the radiosensitizing effect of AKT inhibition and reduced cell viability in malignant glioma cells U87-MG and U87-MGΔEGFR[@ref78]. The same group showed that AKT inhibition resulted in decreased phosphorylated p70S6 kinase, a downstream target of AKT, and induced autophagy, but not apoptosis. Also, the AKT inhibitor radiosensitized both U87-MG and U87-MGΔEGFR cells by enhancing autophagy. Further studies need to be done to identify the mechanism(s) involved in the cytoprotective effect of radiation-induced autophagy and cytotoxic effect of Akt induced autophagy on post-irradiation survival.

***Tumour cell proliferation***: The detrimental effect of cellular repopulation for tumour control has been extensively studied in various malignancies[@ref79]. Tumour repopulation is affected by various factors such as cell differentiation status, cell-cycle gene regulation, and micro-environmental factors, including oxygen, neoangiogenesis and nutrient availability. A major mechanism by which cellular proliferation is enhanced in response to ionizing radiation is by induction of EGFR phosphorylation[@ref80]. This EGFR response has been linked to several crucial components of mitogenic or proliferative signaling pathways, a major route being the RAS/RAF/mitogen-activated protein kinase (MAPK) pathway[@ref80]. Studies on PI3-K/AKT have mainly focused on its role in cell survival and progression[@ref81]. Additionally, this PI3-K/AKT also amplifies tumour cell proliferation by signaling the cell cycle machinery as AKT phosphorylation prevents cyclin D1 degradation, which regulates transition of tumour cells from G1 to S phase of cell cycle resulting in radiation resistance[@ref82][@ref83].

***Hypoxia and angiogenesis***: Solid tumours are known to have an imbalance between oxygen delivery and oxygen consumption, resulting in hypoxia. Tumour hypoxia promotes genetic instability, thus leading the tumour towards a more malignant phenotype by stimulating the invasion of tumour cells and, therefore, metastasis[@ref84]. Furthermore, hypoxia modulates mutations of key regulatory genes that result in overexpression of various protein products of these genes which induce resistance to treatment, resulting in an overall adverse clinical outcome[@ref85][@ref86].

PI3-K/AKT signaling has an important role in this adaptive response of tumour cells to hypoxia. As all these hypoxia-related markers are under the control of AKT, information on AKT-activation status may add significantly to the predictive potential of endogenous tumour markers. Tumour hypoxia results in increased expression of hypoxia-inducible transcription factor- 1(HIF-1), which modulates the expression of many genes involved in angiogenesis, *p*H regulation, and glucose metabolism which in turn drive tumour growth and progression. The protein products of these genes, such as vascular endothelial growth factor (VEGF), carbonic anhydrase-IX, the glucose transporters Glut-1 and Glut-3, osteopontin and tyrosine hydroxylase have now been recognized as potential predictive markers for clinical outcome in various tumours[@ref87]. The interaction between hypoxia, angiogenesis and PI3-K/AKT has been shown in various malignancies[@ref88][@ref89][@ref90][@ref91] and has been further corroborated by the evidence that downregulation of this signaling pathway by protease inhibitor nelfinavir resulted in decreased expression of HIF-1α and VEGF in response to radiation[@ref92]. Another hypoxia-related product that is under the control of the PI3-K/AKT pathway is osteopontin which is increased in several tumours in response to hypoxia. Hypoxia-induced activation of AKT has been shown to activate an unknown transcriptional factor that triggers osteopontin expression[@ref93][@ref94].

Under hypoxic conditions, VEGF is one of the genes which are activated by HIF-1; while under normoxic conditions it is activated through PI3-K/AKT signalling by either upregulation of EGFR or loss of PTEN[@ref92][@ref95]. VEGF expression plays an important role in neo-angiogenesis by inducing endothelial cell proliferation and vascular permeability crucial for tumour cell proliferation. Prevention of neo-angiogenesis by downregulation of VEGF either directly by the use of VEGF inhibitors such as bevacizumab or indirectly through the use of PI3K/AKT inhibitors or EGFR inhibitors can result in a normalization of the vasculature and improved perfusion leading to a reduction of tumour cell hypoxia[@ref96]. Two distinct pathways (one including HIF-1α translation and the other involving HIF-independent processes) have been recognized as regulators of VEGF expression, both of which involve PI3-K and AKT[@ref92]. Morelli *et al*[@ref97] observed that VEGF-A blockade, by EGFR inhibition, significantly decreased angiogenesis. A sustained control of tumour cell proliferation and angiogenesis was obtained by the combined blockade of the EGFR pathway in the tumour and the VEGF pathway in endothelial cells. These findings highlight the close relation between EGFR and VEGF inhibition and downstream signal transduction via the PI3-K/AKT pathway. This is corroborated by *in vitro* experiments using PI3-K inhibitor LY294002 which interrupts the PI3-K/AKT pathway resulting in decreased VEGF expression[@ref98].

***AKT signalling and glucose metabolism leading to tumour radioresistance***: Cancer cells tend to exhibit increased glucose metabolism compared to normal cells leading to excess lactate production by the process of aerobic glycolysis, also called Warburg effect[@ref99][@ref100][@ref101]. AKT hyperactivation is believed to be associated with increased rates of glucose metabolism observed in tumour cells[@ref102]. This may be through several mechanisms such as, regulation of GLUT-1 on plasma membrane[@ref103], hexokinase expression and mitochondrial protection[@ref104], or Akt may indirectly activate the glycolysis rate-controlling enzyme phosphofructokinase-1 (PFK1) by direct phosphorylation of phosphofructokinase-2 (PFK2)[@ref105], resulting in formation of fructose-2.6-bisphosphate (Fru-1,6-P2), which is a potent allosteric activator of PFK1. *In vitro* study on glioblastoma cell lines showed that AKT activation correlated with increased glycolysis in glioblastoma cells and tumour cell resistance[@ref102]. Therefore, it can be postulated that the increased glycolytic rates observed by Warburg in cancer cells exhibiting mitochondrial respiration malfunction compared to normal cells may involve activation of the Akt pathway. Inhibition of glucose metabolism in cancer cells with AKT pathway inhibitors is assumed to limit glycolysis in the cancer cell and thereby the production of pyruvate and regeneration of NADPH leading to increased levels of hydrogen peroxide and hydroperoxides resulting in preferential cytotoxicity of the cancer cells via oxidative stress. Based on these assumptions, the combination of Akt pathway inhibitors with glycolytic inhibitors and/or manipulations that increase pro-oxidant production should further and preferentially cause cytotoxicity in cancer cells, with minimal to no toxicity to normal cells. Simon *et al*[@ref106] using human head neck squamous cell carcinoma (HNSCC) cell lines (FaDu & cal -27) have shown that inhibition of AKT pathway disrupts glucose metabolism and induces metabolic oxidative stress in cancer cells leading to preferential cytotoxicity. These results indicate that increased Akt pathway signalling may have a significant role in the Warburg effect and this phenomenon should be exploited to selectively target cancer cells for enhancing radio- and chemo-sensitivity in cancer therapy.

Rationale for targeting the AKT pathway for radiosensitization {#sec1-3}
==============================================================

The P13-K/AKT pathway is a ubiquitous and evolutionary conserved pathway which triggers a cascade of downstream events that regulate various cellular functions namely, cell growth and proliferation, cell survival and motility which drives tumour progression and mediates repair of the damaged DNA resulting in radiation resistance[@ref81][@ref107]. Activation of this pathway and increased intratumoral phosphorylated AKT have been linked to decreased radiation responsiveness in various malignancies[@ref62][@ref89][@ref107].

Clinical evidence of PI3-K/AKT pathway deregulation in various cancers and the identification of downstream kinases involved in mediating the effects of PI3-K/AKT pathway such as the mammalian target of rapamycin (mTOR), pyruvate dehydrogenase kinase 1 (PDK1) and integrin-linked kinase (ILK) provide potential targets for the development of small molecule therapies. Presently, PI3-K/AKT pathway inhibitors are being studied extensively for their radiosensitization properties. Moreover, strong and independent associations have been found between expression of activated AKT (pAKT) and treatment outcome in clinical trials[@ref49][@ref108]. The AKT signal transduction pathway is appealing target for therapeutic intervention, because AKT signalling promotes the three major radioresistance mechanisms (*i.e.* cell survival, tumour cell proliferation and hypoxia)[@ref62][@ref88][@ref92]. Therefore, modulation of AKT signalling pathway may have major implications in the radiotherapeutic management especially in tumours that have activated PI3-K/AKT cascade. Inhibition of the pathway can induce apoptosis or sensitize tumour cells to undergo apoptosis in response to radiation therapy. Extensive *in vitro* and *in vivo* studies have shown that AKT signalling pathway plays an important role in radiation resistance, targeting this pathway to identify drugs that counteract radiation induced cellular defence mechanisms would be logical[@ref92][@ref109][@ref110][@ref111][@ref112]. It has been shown that PI3-K/AKT pathway is selectively activated in human cancer cells and sparing the normal cells, suggesting that factors in this cascade are potential molecular target to improve radiosensitivity[@ref113]. Because of the differential activation of this pathway in tumour cells vs. the normal cells, strategies to block PI3-K/AKT signalling should result in more effective radiation treatment by enhancing the sensitivity of tumour cells to radiation *vis-a-vis* sparing normal tissues surrounding the tumour[@ref109][@ref113]. However, the problem has been to identify inhibitors of this pathway that are suitable for clinical use. For example, *in vitro* studies by Gupta *et al*[@ref113] have shown that LY294002 and wortmannin are potent PI3-K inhibitors with significant radiosensitizing effects but their poor *in vivo* tolerability limits their clinical applications. Currently, the research is being aimed to develop drugs targeting the PI3-K/AKT pathway that are clinically safe. In this context, HIV protease inhibitors have been shown to inhibit AKT phosphorylation and thus radiosensitize tumour cells at concentrations used for anti-HIV treatment. These drugs have been used for over a decade to treat patients with HIV infection and are considered safe for oral use.

HIV protease inhibitors (HPI) as radiosensitizers: mechanism of radiosensitization {#sec1-4}
==================================================================================

The mechanism of radiosensitization is a combination of proteosome inhibition, induction of cell stress, influence on cell signalling cascades, and autophagy[@ref110]. HPIs are selective peptidomimetic, protease inhibitors that bind with high affinity to the active site of HIV protease. The radiosensitizing property of HPIs mainly relates to the inhibition of proteosome which is responsible for degradation of proteins[@ref114]. These compounds inhibit the 20S ribosome which in turn results in endoplasmic reticulum stress triggering the unfolded protein response (UPR) which activates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α) by phosphorylation. The activation of elf2α increases the production of growth arrest and DNA damage-inducible protein (GADD34) which forms a complex with protein phosphatase 1 and induces the downregulation of Phospho-AKT ([Figure](#F1){ref-type="fig"})[@ref114]. The AKT2 isoform, regulates the growth of and metabolism of cells by the insulin/insulin like growth factor signalling pathway[@ref115][@ref116]. This explains some of the adverse effects of HIV protease inhibitors including hyperlipidaemia, insulin resistance, peripheral lipoatrophy, central fat accumulation, and hepatic steatosis. It is possible that the insulin resistance caused by nelfinavir could be related to the decrease in Akt phosphorylation[@ref113]. An alternate downstream event of inhibition of proteosome leads to stabilization of IκB cellular inhibitory protein of NF-kappa B[@ref110]. This results in inactivation of NF-Kappa B leading to apoptosis, reduced tumour cell survival and, therefore, enhanced radiosensitivity[@ref117]. Additionally, AKT dephosphorylation also inactivates HIF-1α and VEGF leading to enhanced tumour oxygenation and inhibition of neoangiogenesis[@ref92][@ref118]. This indirectly enhances tumour sensitivity to irradiation ([Figure](#F1){ref-type="fig"}).

![Mechanisms by which HIV protease inhibitors (HPIs) enhance radiosensitivity. Nelfinavir and other HPIs induce endoplasmic reticulum (ER) stress resulting in unfolded protein response (UPR) which leads to phosphorylation of eukaryotic initiation factor 2 α (eIf2α) leading to global inhibition of protein synthesis and reduced tumour cell survival. A second mechanism is by activation of growth arrest and DNA damage-inducible protein (GADD 34) and protein phosphatase1 (PP1) complex that dephosphorylates phospho-AKT to AKT resulting in decreased DNA replication and increased radiosensitivity. Dephosphorylation of AKT also reduces expression of hypoxia inducible factor (HIF1α) and vascular endothelial growth factor f (VEGF) leading to increased tumour cell oxygenation and decreased angiogenesis which indirectly contributes to enhanced radiosensitivity of the tumour. The third mechanism is by inactivation of nuclear factor Kappa-light-chain-enhancer of activated B cells (NF-kB) which leads to apoptosis and reduced tumour cell survival and thereby indirectly enhancing radiosensitivity. Dephosphorylation of pAKT also activates proapoptotic proteins and inactivates antiapoptotic proteins resulting in activation of apoptotic pathway. Adapted and reproduced from [Figure](#F1){ref-type="fig"} of Ref. [@ref114] with permission from publisher, Taylor and Francis.](IJMR-143-145-g002){#F1}

Extensive *in vitro* experiments using Western blot assays and clonogenic assays have shown the potential radiosensitive activity of different classes of HPIs in different cancer cell lines ([Table II](#T2){ref-type="table"}). The results of the *in vitro* experiments were further corroborated in *in vivo* mouse xenograft models using the same class of HPIs[@ref109].

###### 

Cancer cell line studies using nelfinavir (NFV) as radiosensitizer
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Preclinical evidence has shown that HIV protease inhibitors downregulate AKT at dose range that is clinically used for HIV patients. At this dose range, the safety profile of HPIs has been established clinically as well. The HPIs specifically target the tumour tissue only and this makes them the lead compounds to be used as AKT inhibitors and, therefore, as radiosensitizers. Compared to traditional conventional chemotherapy drugs that are used as radiosensitizers, these drugs can be administered orally with high bioavailability, thereby improving patient compliance.

Nelfinavir - the lead HPI as a radiosensitizer {#sec1-5}
==============================================

The radiosensitizing ability of HPIs was first shown in HIV positive patients in whom the peripheral blood leukocytes phospho-AKT levels were downregulated[@ref119]. Patients taking these "active" radiosensitizing protease inhibitors had very low levels of phospho-AKT compared to HIV +ve patients taking either no medications or other antiretroviral regimens[@ref119]. This led to extensive studies (both *in vitro* and *in vivo*) of different classes of HIV protease inhibitors to determine the mechanistic basis of radiation sensitization. Gupta *et al*[@ref109] studied the radiosensitizing ability of five different classes of HPIs (nelfinavir, amprenavir, sequinavir, ritonavir and indinavir) against different cancer cell lines and normal cells (fibroblasts) both *in vitro* as well as *in vivo*. They observed that three of the five HPIs (saquinavir, amprenavir and nelfinavir) showed potent inhibition of 473 serine AKT phosphorylation in the cancer cell lines but not in the normal rat fibroblasts. Nelfinavir, amprenavir and saquinavir were also shown to radiosensitize human umbilical vein endothelial cells (HUVEC) and tumour vascular endothelium along with inhibition of angiogenesis and tumour cell migration[@ref120]. Of the three HPIs, nelfinavir had more profound effect on HUVEC and tumour vascular endothelium. *In vitro* pharmacokinetic studies done on SQ20B (head and neck cancer) and T24 (bladder cancer) have shown that low concentration (5 micromol/l) of nelfinavir was enough to downregulate pAKT in comparison to saquinavir and amprenavir (10 micromol/l)[@ref109]. Additionally, nelfinavir was found to be least toxic among all the HPIs, thus making it a lead AKT inhibitor for clinical use as a radiosensitizing agent. The most common side effect of this drug is diarrhoea occurring in 30 per cent patients[@ref121] which is usually mild to moderate and controlled with over the counter antidiarrhoeal drugs. Hyperlipidaemia, hyperglycemia and elevation of transaminases (especially in patients with hepatitis B and C infection due to immune reconstitution) have been reported with long term use of nelfinavir[@ref122]. [Table II](#T2){ref-type="table"} summarizes the mechanism of radiosensitization of nelfinavir in different cancer cell lines.

*In vivo* studies have shown that the oral bioavailability of nelfinavir is 70-80 per cent in fed state. Food increases nelfinavir exposure and decreases nelfinavir pharmacokinetic variability relative to the fasted state. Exposure to nelfinavir is 2-5 fold higher in fed state compared to fasting state. Nelfinavir exposure increases with increasing calorie or fat content of meals. The drug is extensively bound to plasma proteins (\>98%) with a plasma half-life of 3.5-5 h. The majority of an oral dose is excreted in the faeces as oxidative metabolites. Only 1-2 per cent of the drug is excreted unchanged through the kidneys.

Clinical trials of nelfinavir as radiosensitizer {#sec1-6}
================================================

With the availability of preclinical data (*in vitro* & *in vivo*) of nelfinavir as a potent radiosensitizing agent, various phase-I and phase-II clinical trials have been initiated. First phase-I clinical trial using nelfinavir was carried out against locally advanced pancreatic cancer. This study showed that the toxicity of nelfinavir along with chemoradiation (radiation dose of 59.4 Gy + gemcitabine and cisplatin) was low with favourable tumour response (metabolic complete response 'CR' in 56% patients)[@ref124]. Another phase-I study of nelfinavir with concurrent chemoradiation (radiation dose of 66.6Gy +cisplatin and etoposide) in stage IIIA/IIIB non-small cell lung cancer (NSCLC) showed acceptable toxicity and promising activity in patients with locally advanced NSCLC (metabolic CR in 56% patients and partial response in 44%)[@ref125]. Recently, a third phase-I study of nelfinavir in combination with capecitabine in rectal cancer (radiation dose of 50.4 Gy) showed promising results with acceptable toxicity and a pathological complete response of 33 per cent[@ref126]. Till date, only these three studies have reported the results of radiation therapy with concomitant nelfinavir along with conventional chemotherapy as radiosensitizer in clinical settings[@ref124][@ref125][@ref126]. Both clinical trials have reported grade 3-4 haematologic toxicities attributable to chemotherapy drugs (cisplatin, etoposide and gemcitabine used in these trials). The rectal cancer study had grade-3 lower gastrointestinal (GI) toxicity in the form of diarrhoea. However, all the patients in these three trials could complete their planned treatment. Grade 1 and 2 toxicities were reported in almost all the patients, especially hyperglycaemia, elevated transaminases and lower GI toxicities which were transient and self-limiting. Currently, numerous clinical trials are in progress to test nelfinavir as a radiosensitizer. The details of the clinical trials are summarized in [Table III](#T3){ref-type="table"}. Although the present clinical evidence is still immature, the results of these clinical trials are eagerly awaited to see if nelfinavir actually has the potential to be put into clinical use as a radiosensitizer for various cancers.

###### 

Clinical trials using concurrent nelfinavir and chemotherapy as radiosensitizing agent in HIV seronegative malignant tumours\*
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Conclusion {#sec1-7}
==========

The role of AKT in cancer has been a subject of discussion over the past decade. It is clear that activation of the AKT pathway is one of the most common molecular alterations in human malignancy conferring to radioresistance thereby providing a strong rationale for targeting the AKT pathway as radiosensitizers. The use of commercially available drugs such as the HPIs is an initial step towards targeting the AKT pathway and these need to be used in clinical radiotherapy trials along with conventional drugs to enhance radiosensitivity of tumours.

Although the complete mechanism of action of HPIs as radiosensitizing agent is not yet completely understood, its broad spectrum of activity, minimal toxicity, and its availability in clinics has made these compounds to be used in cancer therapeutics as a radiosensitizer. Extensive preclinical evidence and ongoing phase-I clinical trials support the use of HPIs with radiation where the effects could be monitored in the patients. Moreover, the tolerability of these compounds has been documented which makes them ideal to be tested in future phase-II and phase-III studies as radiosensitizers.
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